Detection and Assessment of Tumor Response
Category RECIST RECIST 1.1 mRECIST WHO EASL CR (complete response) Disappearance of all target lesions (up to five measurable liver lesions) Disappearance of all target lesions (up to two measurable…
Category RECIST RECIST 1.1 mRECIST WHO EASL CR (complete response) Disappearance of all target lesions (up to five measurable liver lesions) Disappearance of all target lesions (up to two measurable…
Author, year Radiological tumor response Biomarkers tumor response N, type of microspheres Size1 Size + Necrosis2 TTP ORR (CR + PR) DCR (CR + PR + SD) ORR (CR +…
Reference, year Device Lobar FUP interval No. patients Cirrhosis Child B Grade > 3 Bilirubina Ascites Findings (Dancey et al. 2000) Glass 0 % nr 22 nr nr 22 %* nr 2 potential REILD-related…
Carretero C, Munoz-Navas M, Betes M et al (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102:1–5CrossRef Covey AM, Brody LA, Maluccio MA, Getradjdman GJ, Brown KT…
Radiation-induced segmentectomy for patients unfit for ablation or embolization Radiation-induced hepatectomy associated with tumor treatment, for patients unfit for surgery because of comorbidities or insufficient remnant liver Downstaging procedure for…
Fig. 1 76yr male with metastatic carcinoid to his liver. He has had the carcinoid syndrome daily for the last 3 years and was treated with long acting octreotide injections. However, the…
Author N Setting Response PET response TTP OS Comments Bester 224 Refractory NA NA NA 11.9 m Comparative retrospective cohort study with BSC. Reduction of 43 % in the hazard of death…
Author Pat. # Therapy Response (PR, CR, SD) Survival Comment (D’Avola et al. 2009) 35 35 RE (resin) 16 m 8 m Comparison to not-in-study- included control group (Woodall et al. 2009)…
Fig. 1 Illustration of the 90Y microsphere radioembolization showing microcatheter in the hepatic artery releasing radioactive microspheres in the dominant flow leading to a tumor Fig. 2 Two possible scenarios depending on…
Fig. 1 Potential points of integration of RE into the treatment pathway of patients with liver-only or liver-dominant unresectable colorectal liver metastases. The shaded box shows clinical trials testing RE with…